Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 56-62

  Goodman, L ^a   Torres, B ^a   Punke, J ^b   Reynolds, L ^a   Speas, A ^a   Ellis, A ^a   Budsberg, S ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Canine; Eicosanoid; Firocoxib; Gastric healing; Tepoxalin

Indexed keywords

3 (CYCLOPROPYLMETHOXY) 4 (4 METHYLSULFONYLPHENYL) 5,5 DIMETHYLFURANONE; 3-(CYCLOPROPYLMETHOXY)-4-(4-METHYLSULFONYLPHENYL)-5,5-DIMETHYLFURANONE; DRUG DERIVATIVE; GAMMA BUTYROLACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PYRAZOLE DERIVATIVE; SULFONE; TEPOXALIN; THROMBOXANE B2;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOPSY; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; MALE; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STOMACH DISEASE; STOMACH MUCOSA; WOUND HEALING;

4-BUTYROLACTONE; ALPROSTADIL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CROSS-OVER STUDIES; DINOPROSTONE; DOG DISEASES; DOGS; FEMALE; GASTRIC MUCOSA; MALE; PYRAZOLES; STOMACH DISEASES; SULFONES; THROMBOXANE B2; WOUND HEALING;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349190380     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0226.x     Document Type: Article

References (39)

1. Hirose M, Miwa H, Kobayashi O, et al. Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, JTE522, is also mediated by a PGE2-independent pathway. Aliment Pharmacol Ther 2002;16(Suppl 2):83-89.
2. Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005;50(Suppl 1):S24-S33.
3. Schmassmann A, Zoidl G, Peskar BM, et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. Am J Physiol Gastrointest Liver Physiol 2006;290:G747-G756.
4. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-397.
5. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-454.
6. Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: A potential mediator of inflammation. J Pharm Pharmacol 1980; 32:517-518.
7. Pettipher ER, Salter ED, Breslow R, et al. Specific inhibition of leukotriene B4 (LTB4)-induced neutrophil emigration by 20-hyd-roxy LTB4: Implications for the regulation of inflammatory responses. Br J Pharmacol 1993;110:423-127.
8. Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 2003;38:645-659.
9. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78:3887-3891.
10. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001;294:1871-1875.
11. Asako H, Kubes P, Wallace J, et al. Indomethacin-induced leukocyte adhesion in mesenteric venules: Role of lipoxygenase products. Am J Physiol 1992;262:G903-G908.
12. Hudson N, Balsitis M, Everitt S, et al. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-747.
13. Muscara MN, Vergnolle N, Lovren F, et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000;129:1423-1430.
14. Asako H, Kubes P, Wallace J, et al. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992;103:146-152.
15. Yamagiwa S, Yoshida Y, Halder RC, et al. Mechanisms involved in enteropathy induced by administration of nonsteroidal antiinflammatory drugs (NSAIDS). Dig Dis Sci 2001;46:192-199.
16. Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 1993;265:G993-G998.
17. Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991;100:878-883.
18. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990;259:G462-G467.
19. Vaananen PM, Keenan CM, Grisham MB, et al. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992;16:227-240.
20. Wallace JL, McCafferty DM, Carter L, et al. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: Anti-inflammatory without gastropathy? Gastroenterology 1993;105:1630-1636.
21. Kirchner T, Aparicio B, Argentieri DC, et al. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukotrienes Essent Fatty Acids 1997;56:417-423.
22. Gyomber E, Vattay P, Szabo S, et al. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol 1996;11:922-927.
23. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygen-ase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
24. Tanaka A, Hase S, Miyazawa T, et al. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: Relation to various pathogenic events. J Pharmacol Exp Ther 2002;303:1248-1254.
25. Tanigawa T, Watanabe T, Hamaguchi M, et al. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: Possible involvement of PGE2. Am J Physiol Gastrointest Liver Physiol 2004;286:G148-G156.
26. Adair HM. Epithelial mitotic activity in experimental gastric wounds. J Anat 1978;125:401-407.
27. Jones CJ, Streppa HK, Harmon BG, et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 2002;63:1527-1531.
28. Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;271:1399-1408.
29. Agnello KA, Reynolds LR, Budsberg SC. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:966-972.
30. Erickson BA, Longo WE, Panesar N, et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999;81:101-107.
31. Jones MK, Wang H, Peskar BM, et al. Inhibition of angio-genesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
32. Cheng T, Cao W, Wen R, et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998;39:581-591.
33. Waldman SA, Vitow C, Osborne B, et al. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. J Clin Pharmacol 1996;36:462-468.
34. Andrews FM, Reinemeyer CR, McCracken MD, et al. Comparison of endoscopic, necropsy and histology scoring of equine gastric ulcers. Equine Vet J 2002;34:475-478.
35. Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47(Suppl2):S93-S101.
36. Shen H, Sun WH, Xue QP, et al. Influences of Helicobacter pylori on cyclooxygenase-2 expression and prostaglandinE2 synthesis in rat gastric epithelial cells in vitro. J Gastroenterol Hepatol 2006;21:754-758.
37. Hudson N, Balsitis M, Filipowicz F, et al. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748-751.
38. Strauss-Ayali D, Simpson KW, Schein AH, et al. Serological discrimination of dogs infected with gastric Helicobacter spp. and uninfected dogs. J Clin Microbiol 1999;37:1280-1287.
39. Henry GA, Long PH, Burns JL, et al. Gastric spirillosis in beagles. Am J Vet Res 1987;48:831-836.